ATX GD 59

Drug Profile

ATX GD 59

Alternative Names: ATX-GD-59

Latest Information Update: 20 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Apitope Technology
  • Class Peptides
  • Mechanism of Action Thyrotropin stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Graves' disease

Most Recent Events

  • 16 Apr 2018 Efficacy data from a phase I trial in Graves' disease released by Apitope Technology
  • 15 Mar 2018 Apitope plans to initiate a phase II study in Graves' disease in the first quarter of 2019 (Apitope Technology pipeline, March 2018)
  • 15 Mar 2018 ATX GD 59 is available for licensing as of 15 Mar 2018. https://apitope.com/partnering/
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top